Skip to main content
OpenTrials

Clinical trial condition

Refractory Multiple Myeloma

Explore clinical trials studying Refractory Multiple Myeloma. Study availability and eligibility vary by location and protocol.

153 public trials 23 recruiting studies
Refine in advanced search Browse all conditions

Refractory Multiple Myeloma trial results

Completed

Study of Carfilzomib, Daratumumab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma.

NCT03158688

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +14 more
Locations
  • Lynn Cancer Center Boca Raton Regional Hospital, Lynn Cancer Institute Boca Raton, Florida, United States
  • Emory University Winship Cancer Institute Atlanta, Georgia, United States
  • University of Chicago Medical Center - Multiple Myeloma Research Consortium Chicago, Illinois, United States
  • Fort Wayne Medical Oncology and Hematology Fort Wayne, Indiana, United States
View all 113 locations
View Trial Details
Completed

TJ202 Combined With Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma

NCT03860038

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +14 more
Locations
  • Beijing Chao-Yang Hospital,Capital medical university Beijing, Beijing Municipality, China
  • Peking Union Medical College Hospital Beijing, Beijing Municipality, China
  • Fujian Medical University Union Hospital Fuzhou, Fujian, China
  • Nanfang Hospital of SMU Guangzhou, Guandong, China
View all 18 locations
View Trial Details
Completed

A Study of ION251 Administered to Patients With Relapsed/Refractory Multiple Myeloma

NCT04398485

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +14 more
Locations
  • University of California San Diego Moores Cancer Center La Jolla, California, United States
  • Cedars-Sinai Medical Center Los Angeles, California, United States
  • UCLA Rrmc Los Angeles, California, United States
  • Barbara Ann Karmanos Cancer Institute Detroit, Michigan, United States
View Trial Details
Completed

A Study Evaluating The Safety And Pharmacokinetics Of Escalating Doses Of RO7297089 In Patients With Relapsed Or Refractory Multiple Myeloma

NCT04434469

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +14 more
Locations
  • Concord Repatriation General Hospital Concord, New South Wales, Australia
  • LIVERPOOL HOSPITAL; HAEMATOLOGY; Ingham Institute for Medical Research Liverpool, New South Wales, Australia
  • Royal Adelaide Hospital; Haematology Clinical Trials Adelaide, South Australia, Australia
  • St. Vincent's Hospital Melbourne Fitzroy, South Australia, Australia
View Trial Details
Completed

TJ202, Lenalidomide and Dexamethasone vs. Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma

NCT03952091

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +14 more
Locations
  • Capital Medical University (CMU) - Beijing Chao-Yang Hospital Beijing, Beijing Municipality, China
  • Peking University Third Hospital Beijing, Beijing Municipality, China
  • Capital Medical University (CMU) - Beijing Chao-Yang Hospital Beijing, Beijing Municipality, China
  • The First Affiliated Hospital of Bengbu Medical college Bengbu, China
View all 41 locations
View Trial Details
Completed

Wild-Type Reovirus in Combination With Carfilzomib and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma

NCT02101944

Conditions
Anemia, Blood Protein Disorders, Cardiovascular Diseases, +15 more
Locations
  • Emory University Hospital/Winship Cancer Institute Atlanta, Georgia, United States
  • Ohio State University Comprehensive Cancer Center Columbus, Ohio, United States
  • Huntsman Cancer Institute/University of Utah Salt Lake City, Utah, United States
View Trial Details
Completed

A Phase 3 Study Comparing Oral Ixazomib Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma

NCT01564537

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +14 more
Locations
  • University of Arkansas Medical Sciences Little Rock, Arkansas, United States
  • Pacific Cancer Medical Center Inc Anaheim, California, United States
  • West Contra Costa Healthcare District Berkeley, California, United States
  • University of Florida Gainesville, Florida, United States
View all 24 locations
View Trial Details

Related conditions